DexCom $DXCM jumps 4% as its landmark CONNECT trial lands in The New England Journal of Medicine. It backs continuous glucose monitors, sensors that track blood sugar all day, for Type 2 diabetes patients not on insulin. @petenajarian @jonnajarian check the vitals because #ITSNOTANOPTION 📙 Virtual RebelCon Oct 20-21 $295 👉 https://t.co/UVTvPf5mbG
View on X ↗